Armon Comments on the Importance of Companies Implementing Compliance Programs Early

Armon Comments on the Importance of Companies Implementing Compliance Programs Early

"Compliance Alert for Drug Sales & Marketing", ePharmaceuticals

December 21, 2005

Bruce D. Armon, a Partner and Chair of the Regulatory, Privacy, and Healthcare Contracting Practice Group in the Philadelphia office, was quoted in this article about the need for companies to begin developing and implementing their compliance programs early.

The article examines the recent settlement, announced in October, in which an affiliate of Serono, Inc., the makers of the AIDS wasting treatment Serostim, pleaded guilty to two counts of conspiracy related to illegally promoting, marketing, and selling of the treatment.

"Serono's payment to resolve criminal charges and civil liabilities reiterates the need for all pharmaceutical companies to develop, refine, and maintain compliance programs," Mr. Armon said.